Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Vinva Investment Management Ltd

Vinva Investment Management Ltd decreased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 14.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,098 shares of the biopharmaceutical company’s stock after selling 2,848 shares during the period. Vinva Investment Management Ltd’s holdings in Royalty Pharma were worth $433,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of RPRX. Swedbank AB grew its stake in Royalty Pharma by 10.3% during the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after buying an additional 1,136,800 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Royalty Pharma by 58.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock worth $84,915,000 after buying an additional 1,103,341 shares during the period. Two Sigma Advisers LP grew its stake in Royalty Pharma by 44.7% during the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after buying an additional 936,900 shares during the period. Raymond James Financial Inc. purchased a new stake in Royalty Pharma during the fourth quarter worth approximately $19,990,000. Finally, Point72 Asset Management L.P. purchased a new stake in Royalty Pharma during the third quarter worth approximately $14,898,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Up 0.6 %

RPRX stock opened at $33.70 on Friday. The firm’s 50-day moving average is $32.25 and its two-hundred day moving average is $28.72. The company has a market capitalization of $19.43 billion, a price-to-earnings ratio of 23.24, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were paid a $0.22 dividend. The ex-dividend date of this dividend was Friday, February 21st. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a yield of 2.61%. Royalty Pharma’s payout ratio is 60.69%.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and an average target price of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.